Literature DB >> 26475777

Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer.

Hee Jin Lee1, In Ah Park1, In Hye Song1, Su-Jin Shin2, Joo Young Kim3, Jong Han Yu4, Gyungyub Gong1.   

Abstract

BACKGROUND: Tumour-infiltrating lymphocytes (TILs) have a strong prognostic significance, particularly in triple-negative breast cancer (TNBC). One important source of TILs in breast cancer is tertiary lymphoid structures (TLSs).
OBJECTIVE: To carry out a histological analysis of surgically resected TNBC to identify the location of TLSs, the relationship between TLSs and TILs and their prognostic significance in TNBC.
METHODS: We retrospectively analysed 769 patients with TNBC.
RESULTS: TILs were defined as the percentage of stroma of invasive carcinoma infiltrated by lymphocytes. TLSs were mainly present within adjacent terminal duct lobular units and around in situ components. TNBC with higher levels of TILs showed a higher nuclear grade, lower lymphovascular invasion, less accompanying in situ component, a homogeneous growth pattern, necrosis in invasive areas, low levels of tumour stroma, high levels of peritumoral lymphocytic infiltration and moderate to abundant TLSs in adjacent tissue. TILs, the degree of peritumoral lymphocytic infiltration and adjacent TLSs were prognostic factors for disease-free and overall survival. Although the TIL level did not have a prognostic value in stage I, it added significant prognostic information for stages II and III. Conversely, patients with high levels of TILs did not show prognostic differences according to the pTNM stage. Patients with high levels of TILs (> 60%) and moderate to abundant TLSs had significantly better disease-free survival than those with high levels of TILs but none or few TLSs.
CONCLUSIONS: TLSs are frequently present in TNBC and are closely associated with TILs. TILs provide additional prognostic information in patients with TNBC with a higher pTNM stage. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  BREAST CANCER; HISTOPATHOLOGY; TUMOUR IMMUNITY

Mesh:

Year:  2015        PMID: 26475777     DOI: 10.1136/jclinpath-2015-203089

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  50 in total

Review 1.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.

Authors:  Xia Liu; Julia Y S Tsang; Thazin Hlaing; Jintao Hu; Yun-Bi Ni; Siu Ki Chan; Sai Yin Cheung; Gary M Tse
Journal:  Oncologist       Date:  2017-07-12

Review 3.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

4.  Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Authors:  Laurence Buisseret; Christine Desmedt; Soizic Garaud; Marco Fornili; Xiaoxiao Wang; Gert Van den Eyden; Alexandre de Wind; Sebastien Duquenne; Anais Boisson; Celine Naveaux; Francoise Rothé; Sandrine Rorive; Christine Decaestecker; Denis Larsimont; Martine Piccart-Gebhart; Elia Biganzoli; Christos Sotiriou; Karen Willard-Gallo
Journal:  Mod Pathol       Date:  2017-06-16       Impact factor: 7.842

5.  Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.

Authors:  Joo Young Kim; Sun-Hee Heo; Seul Ki Choi; In Hye Song; In Ah Park; Young-Ae Kim; Hye Seon Park; Suk Young Park; Won Seon Bang; Gyungyub Gong; Hee Jin Lee
Journal:  Virchows Arch       Date:  2017-02-09       Impact factor: 4.064

6.  Lymphatic drainage from bronchus-associated lymphoid tissue in tolerant lung allografts promotes peripheral tolerance.

Authors:  Wenjun Li; Jason M Gauthier; Alice Y Tong; Yuriko Terada; Ryuji Higashikubo; Christian C Frye; Margaret S Harrison; Kohei Hashimoto; Amit I Bery; Jon H Ritter; Ruben G Nava; Varun Puri; Brian W Wong; Kory J Lavine; Ankit Bharat; Alexander S Krupnick; Andrew E Gelman; Daniel Kreisel
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

Review 7.  Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.

Authors:  Nicolas A Giraldo; J David Peske; Catherine Sautès-Fridman; Wolf H Fridman
Journal:  Virchows Arch       Date:  2019-01-10       Impact factor: 4.064

Review 8.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

Review 9.  Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.

Authors:  Anthony B Rodriguez; Victor H Engelhard
Journal:  Cancer Immunol Res       Date:  2020-11       Impact factor: 11.151

Review 10.  Mechanism of tumour microenvironment in the progression and development of oral cancer.

Authors:  Mohd Mughees; Anindita Sengupta; Sapna Khowal; Saima Wajid
Journal:  Mol Biol Rep       Date:  2021-01-25       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.